We use our own cookies and third-party cookies to improve our services and analyse the browsing habits of our users. Continuing to browse our sites implies full acceptance of their use. You can change your cookie setting or get more information here

Sanifit Therapeutics S.A.

Sanifit Therapeutics S.A.


Sanifit is a biopharmaceutical company dedicated to the development of SNF472, an experimental drug for the treatment of cardiovascular disease in patients with End Stage Renal Disease (ESRD) treated with hemodialysis. The company, which was founded in 2007 as a spin off of the University of the Balearic Islands, has completed Phase I clinical studies in healthy volunteers and hemodialysis patients. In 2015 Sanifit closed a series C round of EUR 36.6 million that has allowed him to start a Phase IIb study in ESRD and extend its program calciphylaxis to clinical trials phase II / III.


Product Type of product Therapeutic Area Indication Development Phase
SNF472 Drug Nefrología Enfermedad cardiovascular Phase II / Clinical Validation
SNF472 Drug Nefrología Calcifilaxis Phase II / Clinical Validation
SNF671 Biological & Natural Trastornos de calcificación Osteoporosis No pre-clinical regulatory / R+D
ASB01 Biological & Natural Odontología Sarro Market
Phytech Device Ortopedia Osteointegración No pre-clinical regulatory / R+D
LitControl Device Diagnóstico Litiasis Renal Market


Therapeutic pipeline:

  • SNF472: treatment of cardiovascular disease in hemodialysis patients (in phase II).
  • SNF472: treatment of calciphylaxis (in phase II).

OCT pipeline:

  • LitControl: diagnostic of renal lithiasis (kidney stones). Licensed to Devicare.
  • ASB01: treatment of dental calculi. Licensed to GSK.
  • SNF671: for bone disorders.
  • Phytech: bioactive titanium implants to improve osseointegration.


New approach to calcification disorders.

Market/ Developement areas

  • Cardiovascular calcifications
  • Nephrology
  • Oral diseases
  • Bone diseases



Download sheet